As the leading provider of genomics services and solutions, AGTC Genomics Sdn. Bhd. is the first in Malaysia to have access to the cutting-edge technology that is the Illumina NovaSeq 6000, along with DRAGEN Bio-IT, Illumina’s highly accurate and ultra-rapid secondary analysis software to process the large amount of unprocessed sequenced data produced by the NovaSeq.
Specialities of the Sequencer Technology
The world’s fastest production scale sequencer- the Illumina NovaSeq 6000 – was recently unveiled at The Advanced Genomics Technology Center at AGTC Genomics, Bukit Jalil. This brand-new technology is expected to increase the number of samples sequenced drastically and reduce the cost of precision medicine significantly, enabling researchers and clinicians to read and decipher genetic information more quickly. This information can then be used in the diagnosis of diseases or to help find the best treatment to target cancer cells in patients. The same technology can also be used to fight infectious diseases; most notably, COVID-19 genome sequencing and surveillance.
There is a vital need to make genomic technology and precision medicine available to all. We are inspired by AGTC Genomics and their dedication to increase sequencing capability, and transform healthcare in Malaysia.
Gretchen Weightman, Head of Global Commercial Strategy and General Manager of Asia Pacific and Japan at Illumina
Effects of the NovaSeq 6000 on Malaysians
By enabling the performance of genome sequencing in Malaysia on a national scale, Malaysians will be able to receive more individually tailored therapies which will improve overall patient care. Beyond biomedicine, the new facility (AGTC Genomics Sdn. Bhd) also has exciting applications in the agricultural and environmental industries.
One key area we are keen to use the NovaSeq 6000 sequencer for is to discover new ways to offer the best available treatment for each individual cancer patient’s disease. If we can do this, we should be able to revolutionise how cancer patients are being treated. With the NovaSeq 6000 system, this kind of work is now feasible
Dr Chee-Onn Leong, CEO of AGTC Genomics
For more information on AGTC Genomics and the NovaSeq 6000, visit its website.
